Literature DB >> 3470008

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.

M J Tisdale.   

Abstract

Cell lines with constitutive levels of the DNA repair protein O6-methylguanine-DNA methyltransferase (O6MeGMT) (Mer+ phenotype) were less sensitive to the cytotoxic effects of the imidazotetrazinone mitozolomide and the methyl analogue (CCRG 81045) than cells lacking the repair enzyme (Mer-). In contrast neither chlorambucil or the ethylimidazotetrazinone (CCRG 82019) showed differential toxicity between Mer+ and Mer- cell lines. When Mer+ cell lines were incubated with the free base O6-methylguanine (O6MeG) for 16 hr there was a depletion of O6MeGMT, which was dose-related. Such cells showed an increased sensitivity to both mitozolamide and CCRG 81045, but not to CCRG 82019. The only Mer+ cell line not showing increased sensitization with O6MeG pretreatment was Raji, where O6MeGMT was shown to reappear after addition of CCRG 81045. These results suggest that the chloroethyl and methylimidazole-triazinones are similar to the nitrosoureas and triazenes in that cytotoxicity correlates with alkylation of the O6-position of guanine, while the ethyl analogues appear to produce an alternate cytotoxic lesion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470008     DOI: 10.1016/0006-2952(87)90351-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  30 in total

1.  Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.

Authors:  Veli Çıtışlı; Yavuz Dodurga; Canan Eroğlu; Mücahit Seçme; Çığır Biray Avcı; N Lale Şatıroğlu-Tufan
Journal:  Tumour Biol       Date:  2015-04-03

2.  Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.

Authors:  Ufuk Abacioglu; Hale B Caglar; Perran F Yumuk; Zuleyha Akgun; Beste M Atasoy; Meric Sengoz
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

3.  FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.

Authors:  Nu Zhang; Xinjian Wu; Lixuan Yang; Feizhe Xiao; Heng Zhang; Aidong Zhou; Zhengsong Huang; Suyun Huang
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

4.  Extended-schedule dose-dense temozolomide in refractory gliomas.

Authors:  A Berrocal; P Perez Segura; M Gil; C Balaña; J Garcia Lopez; R Yaya; J Rodríguez; G Reynes; O Gallego; L Iglesias
Journal:  J Neurooncol       Date:  2009-08-08       Impact factor: 4.130

5.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Authors:  K A van Nifterik; J van den Berg; W F van der Meide; N Ameziane; L E Wedekind; R D M Steenbergen; S Leenstra; M V M Lafleur; B J Slotman; L J A Stalpers; P Sminia
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

6.  Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Authors:  W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

7.  Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Authors:  Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

8.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

Review 9.  The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.

Authors:  Wei Wei; Xin Chen; Ximeng Ma; Dawei Wang; Zongze Guo
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

10.  Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.

Authors:  R Banerjee; Z Rachid; Q Qiu; J P McNamee; A M Tari; B J Jean-Claude
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.